Skip to main content
. 2022 Jun 22;6(4):605–617. doi: 10.1007/s41669-022-00334-6

Table 5.

Secondary analysis results

Secondary analysis Total mean cost (£) Total mean QALYs ICER (£)
Daily prednisolone 2690 11.61
Placebo 2866 11.60
Incremental difference 176 − 0.01 Dominated by prednisolone

QALYs quality-adjusted life-years, ICER incremental cost-effectiveness ratio